Octapharma: New Consensus Recommendations on Treatment of Secondary Antibody Deficiency in Patients With Haematological Malignancies
Octapharma: New Consensus Recommendations on Treatment of Secondary Antibody Deficiency in Patients With Haematological Malignancies European Journal of Haematology The publication, sponsored by Octapharma, marks the first pan-European consensus guidance on the use of IgRT in patients with hypogammaglobulinaemia secondary to haematological malignancies and aims to support harmonisation of clinical practice across Europe. Octapharma has a longstanding commitment to improving the management of patients with secondary immunodeficiencies (SID) and in 2020 launched PRO-SID, a phase III clinical tr...